

Supplementary material: Development of Lomustine and *n*-Propyl Gallate Co-encapsulated Liposomes for Targeting Glioblastoma Multiforme via Intranasal Administration

Gábor Katona ^{1,*†}, Fakhara Sabir ^{1,†}, Bence Sipos¹, Muhammad Naveed³, Zsuzsanna Schelz ², István Zupkó ² and Ildikó Csóka ¹

¹ Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 Szeged, Hungary; katona.gabor@szte.hu (G.K.); fakhra.sabir@gmail.com (F.S.); sipos.bence@szte.hu (B.S.); csoka.ildiko@szte.hu (I.C.)

² Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 Szeged, Hungary; schelz.zsuzsanna@szte.hu (Z.S.); zupko@pharm.u-szeged.hu (I.Z.);

³ Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Szeged, Dóm sqr. 12; H-6720 Szeged, Hungary; naveed.muhammad@med.u-szeged.hu (M.N.)

* Correspondence: katona.gabor@szte.hu; Tel.: +36-62-545-575

† These authors contribute equally to this paper.




Figure S1. Stability of liposomal formulations evaluated at different temperatures; 4 °C (A-D) and room temperature (25 °C) (E-H) expressed as Z-average (A and E), zeta potential (B and F), and EE regarding to PG (C and G) and LOM (D and H) over period of four weeks.